Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2017 Nov 30

PMID 29184536

Citations 26

Authors

Roberta Malaguarnera

Veronica Vella

Maria Luisa Nicolosi

Antonino Belfiore

Affiliations

Soon will be listed here.

Abstract

In the past few decades, the incidence of thyroid cancer (TC), namely of its papillary hystotype (PTC), has shown a steady increase worldwide, which has been attributed at least in part to the increasing diagnosis of early stage tumors. However, some evidence suggests that environmental and lifestyle factors can also play a role. Among the potential risk factors involved in the changing epidemiology of TC, particular attention has been drawn to insulin-resistance and related metabolic disorders, such as obesity, type 2 diabetes, and metabolic syndrome, which have been also rapidly increasing worldwide due to widespread dietary and lifestyle changes. In accordance with this possibility, various epidemiological studies have indeed gathered substantial evidence that insulin resistance-related metabolic disorders might be associated with an increased TC risk either through hyperinsulinemia or by affecting other TC risk factors including iodine deficiency, elevated thyroid stimulating hormone, estrogen-dependent signaling, chronic autoimmune thyroiditis, and others. This review summarizes the current literature evaluating the relationship between metabolic disorders characterized by insulin resistance and the risk for TC as well as the possible underlying mechanisms. The potential implications of such association in TC prevention and therapy are discussed.

Citing Articles

Iodine supply and thyroid function in women with gestational diabetes mellitus: a cohort study.

Vitkova H, Anderlova K, Kratky J, Bilek R, Springer D, Votava F Endocr Connect. 2024; 13(11).

PMID: 39212589 PMC: 11466278. DOI: 10.1530/EC-24-0295.

Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs.

Greco A, Coperchini F, Croce L, Magri F, Teliti M, Rotondi M Front Pharmacol. 2023; 14:1303844.

PMID: 38146457 PMC: 10749369. DOI: 10.3389/fphar.2023.1303844.

Subclinical hypothyroidism increases insulin resistance in normoglycemic people.

Yang W, Jin C, Wang H, Lai Y, Li J, Shan Z Front Endocrinol (Lausanne). 2023; 14:1106968.

PMID: 37484968 PMC: 10358968. DOI: 10.3389/fendo.2023.1106968.

Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism.

Li L, Song J, Liu H, Chen C Discov Oncol. 2023; 14(1):23.

PMID: 36811728 PMC: 9947216. DOI: 10.1007/s12672-022-00599-7.

Adherence to the Mediterranean Diet as a Modifiable Risk Factor for Thyroid Nodular Disease and Thyroid Cancer: Results From a Pilot Study.

Barrea L, Muscogiuri G, de Alteriis G, Porcelli T, Vetrani C, Verde L Front Nutr. 2022; 9:944200.

PMID: 35782938 PMC: 9247581. DOI: 10.3389/fnut.2022.944200.

References

Condorelli G, Formisano P, Miele C, Beguinot F . Thyrotropin regulates autophosphorylation and kinase activity in both the insulin and the insulin-like growth factor-I receptors in FRTL5 cells. Endocrinology. 1992; 130(3):1615-25. DOI: 10.1210/endo.130.3.1311244. View

Benetti-Pinto C, Piccolo V, Yela D, Garmes H . Thyroid-stimulating Hormone and Insulin Resistance: Their Association with Polycystic Ovary Syndrome without Overt Hypothyroidism. Rev Bras Ginecol Obstet. 2017; 39(5):224-228. PMC: 10309361. DOI: 10.1055/s-0037-1601436. View

Pellegriti G, De Vathaire F, Scollo C, Attard M, Giordano C, Arena S . Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst. 2009; 101(22):1575-83. DOI: 10.1093/jnci/djp354. View

Roebroek A, Taylor N, Louagie E, Pauli I, Smeijers L, Snellinx A . Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem. 2004; 279(51):53442-50. DOI: 10.1074/jbc.M407152200. View

Park J, Yoo T, Chang T, Lee D, Lee J, Lee J . Insulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients. Metabolism. 2010; 60(1):121-6. DOI: 10.1016/j.metabol.2010.02.006. View

Lin C, Huang H, Chu F, Fan H, Chen H, Chu D . Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. PLoS One. 2015; 10(5):e0125421. PMC: 4433253. DOI: 10.1371/journal.pone.0125421. View

Boelaert K, Syed A, Manji N, Sheppard M, Holder R, Gough S . Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf). 2008; 70(1):129-38. DOI: 10.1111/j.1365-2265.2008.03291.x. View

Brindel P, Doyon F, Rachedi F, Boissin J, Sebbag J, Shan L . Anthropometric factors in differentiated thyroid cancer in French Polynesia: a case-control study. Cancer Causes Control. 2008; 20(5):581-90. DOI: 10.1007/s10552-008-9266-y. View

Ron E, Kleinerman R, Boice Jr J, Livolsi V, Flannery J, Fraumeni Jr J . A population-based case-control study of thyroid cancer. J Natl Cancer Inst. 1987; 79(1):1-12. View

10.

Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C . Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010; 33(9):1997-2003. PMC: 2928350. DOI: 10.2337/dc10-0476. View

11.

Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y . Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J. 2004; 51(2):165-9. DOI: 10.1507/endocrj.51.165. View

12.

Frago S, Nicholls R, Strickland M, Hughes J, Williams C, Garner L . Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist. Proc Natl Acad Sci U S A. 2016; 113(20):E2766-75. PMC: 4878476. DOI: 10.1073/pnas.1513023113. View

13.

Junik R, Kozinski M, Debska-Kozinska K . Thyroid ultrasound in diabetic patients without overt thyroid disease. Acta Radiol. 2006; 47(7):687-91. DOI: 10.1080/02841850600806308. View

14.

Andersson M, Karumbunathan V, Zimmermann M . Global iodine status in 2011 and trends over the past decade. J Nutr. 2012; 142(4):744-50. DOI: 10.3945/jn.111.149393. View

15.

Ahluwalia I, Mack K, Murphy W, Mokdad A, Bales V . State-specific prevalence of selected chronic disease-related characteristics--Behavioral Risk Factor Surveillance System, 2001. MMWR Surveill Summ. 2003; 52(8):1-80. View

16.

Di Donato M, Cernera G, Giovannelli P, Galasso G, Bilancio A, Migliaccio A . Recent advances on bisphenol-A and endocrine disruptor effects on human prostate cancer. Mol Cell Endocrinol. 2017; 457:35-42. DOI: 10.1016/j.mce.2017.02.045. View

17.

Kanamori A, Abe Y, Yajima Y, Manabe Y, Ito K . Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands. J Clin Endocrinol Metab. 1989; 68(5):899-903. DOI: 10.1210/jcem-68-5-899. View

18.

Yin D, Ruan X, Tian X, Du J, Zhao Y, Cui Y . The relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome. Gynecol Endocrinol. 2017; 33(4):332-335. DOI: 10.1080/09513590.2016.1273895. View

19.

Tramontano D, Cushing G, Moses A, Ingbar S . Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology. 1986; 119(2):940-2. DOI: 10.1210/endo-119-2-940. View

20.

Tarantino G, Valentino R, Di Somma C, DEsposito V, Passaretti F, Pizza G . Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin Endocrinol (Oxf). 2012; 78(3):447-53. DOI: 10.1111/j.1365-2265.2012.04500.x. View